Research map: Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects

Back to the article

Papers in this map

  1. How to perform a meta-analysis with R: a practical tutorial · Sara Balduzzi · 2019 · 6001 citations · Cited by this paper
  2. Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms · D. Ye. Ivashchenko · 2026 · Cites this paper
  3. Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy · 2026 · Related
  4. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report · Augustus John Rush · 2006 · 894 citations · Cited by this paper
  5. Understanding response to treatment in depression: Insights from the Pakistani DIVERGE study · Muhammad Umar · 2026 · Cites this paper
  6. Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study · 2025 · Related
  7. The Genetic Ancestry of African Americans, Latinos, and European Americans across the United States · Katarzyna Bryc · 2014 · 759 citations · Cited by this paper
  8. Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study · 2026 · Related
  9. Trends in U.S. Depression Prevalence From 2015 to 2020: The Widening Treatment Gap · Renée D. Goodwin · 2022 · 574 citations · Cited by this paper
  10. A functional ancestry-linked regulatory haplotype influences CYP2D6 expression · 2026 · Related
  11. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study · Jesse Joachim Swen · 2023 · 566 citations · Cited by this paper
  12. Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation · 2026 · Related
  13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants · Chad Bousman · 2023 · 454 citations · Cited by this paper
  14. Genetic markers of early response to lurasidone in acute schizophrenia · 2025 · Related
  15. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients · Marin M. Jukić · 2018 · 224 citations · Cited by this paper
  16. The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study · 2025 · Related
  17. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder · David W. Oslin · 2022 · 205 citations · Cited by this paper
  18. Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States · 2025 · Related
  19. PharmVar GeneFocus: CYP2C19 · Mariana Rodrigues Botton · 2020 · 148 citations · Cited by this paper
  20. Meta-analysis and review of in silico methods in drug discovery – part 1: technological evolution and trends from big data to chemical space · 2025 · Related
  21. Efficient Replication of over 180 Genetic Associations with Self-Reported Medical Data · Joyce Y. Tung · 2011 · 145 citations · Cited by this paper
  22. The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke · 2026 · Related
  23. Pharmacogenomics Clinical Annotation Tool (Pharm CAT ) · Katrin Sangkuhl · 2019 · 130 citations · Cited by this paper
  24. Ancestry Composition: A Novel, Efficient Pipeline for Ancestry Deconvolution · Éric Durand · 2014 · 129 citations · Cited by this paper
  25. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials · Lisa C. Brown · 2022 · 126 citations · Cited by this paper
  26. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review · Elizabeth Jing · 2016 · 122 citations · Cited by this paper
  27. CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System · Yelena Ionova · 2020 · 90 citations · Cited by this paper
  28. Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis · Ming Chang · 2014 · 87 citations · Cited by this paper
  29. Assessing Digital Phenotyping to Enhance Genetic Studies of Human Diseases · Christopher DeBoever · 2020 · 65 citations · Cited by this paper
  30. Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial · Arun Kumar Tiwari · 2022 · 62 citations · Cited by this paper
  31. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT · Xinrui Wang · 2023 · 62 citations · Cited by this paper
  32. Antidepressant Dispensing to US Adolescents and Young Adults: 2016–2022 · Kao‐Ping Chua · 2024 · 56 citations · Cited by this paper
  33. Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study · Adrián I. Campos · 2022 · 51 citations · Cited by this paper
  34. Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder · Cornelis F. Vos · 2023 · 47 citations · Cited by this paper
  35. The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank · Win Lee Edwin Wong · 2023 · 41 citations · Cited by this paper
  36. Reasons for Discontinuation or Change of Selective Serotonin Reuptake Inhibitors in Online Drug Reviews · Su Golder · 2023 · 21 citations · Cited by this paper
  37. Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR *D trial data · Hitoshi Sakurai · 2024 · 14 citations · Cited by this paper
  38. Self‐reported medication use as an alternate phenotyping method for anxiety and depression in the UK Biobank · Megan Skelton · 2021 · 12 citations · Cited by this paper
  39. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States · Ling Zhu · 2022 · 10 citations · Cited by this paper

Source: OpenAlex (CC0)